Antag Therapeutics

Therapeutic peptides for the modulation of GIP biology

Antag Therapeutics is a biotechnology company committed to the development of novel therapeutic peptides for obesity and cardiovascular autonomic diseases.

Antag Therapeutics is based on decades of research from the University of Copenhagen focusing on understanding and targeting incretin physiology. Our therapeutic peptides are based on a novel endogenous peptide antagonist discovered by the research teams of Professors Jens Juul Holst and Mette Rosenkilde that has been characterized in several human intervention studies.

Focus area

Obesity

According to WHO, more than 650 million people worldwide suffer from obesity, and the number increases every year. Obesity leads to comorbidities such as type 2 diabetes, fatty liver disease, stroke, coronary artery disease, cancer and many more. Unfortunately, both dieting, exercise and current pharmacological intervention rarely meet the expectations of physicians and patients.

Postural orthostatic tachycardia syndrome (POTS)

POTS affects 3 million people in the US, predominantly females of child-bearing age, and is characterized by orthostatic intolerance and tachycardia. Patients have reduced quality of life similar to living with chronic obstructive pulmonary disease and congestive heart failure. Unfortunately, there are no approved medications for POTS, so patients rely on ineffective off-label pharmacological and nonpharmacological treatments.

Our first-in-class therapeutic peptides are optimized analogues of an inhibitor of the GIP receptor that is found naturally in the human body

Team

Philip Just Larsen
MD, PhD
Chair
CEO of 6 Peaks Bio with 20 years of experience leading research divisions within the pharmaceutical industry.
Prof. Jens Juul Holst
MD, DMSC
Co-founder
Discoverer of GLP-1, with over 1200 publications. The most cited living physiologist between 1996-2006.
Mark Currie
M.Sc., PhD
Independent
Ironwood BoD, inventor of linaclotide and built and led Ironwood R&D, Co-Founder and President of Cyclerion and inventor of multiple drugs in clinical dev. and currently serves as Chair of SAB
Jeroen Bakker
PhD
Principal at Novo Holdings
Has a broad background in VC, Corporate VC, and biotech consultancy.

Alexander H. Sparre-Ulrich
Chief Executive Officer
M.Sc. PhD
Award winning innovator that has led all commercialization and R&D activities since company inception.

Mads T. Christensen
Chief Scientific Officer
MD PhD
Former Corporate Vice President of Global Obesity and Liver Disease at Novo Nordisk

Richard Nkulikiyinka
Chief Medical Officer
MSc, MB BChir, MRCP
Former Vice President, Head of Therapeutic Area Cardiology, Nephrology & Pulmonology at Bayer

John Boland
Vice President, Clinical Operations
Over 20+ years of regulatory, strategic, and clinical operations experience within autonomic diseases

Sandra C. Cottrell
Head of Regulatory Strategy
M.Sc. PhD
Over 35+ years of regulatory experience (JNJ, Novo Nordisk, NPS Pharm, Chugai, etc.)

Jakob Dynnes Hansen
Chief Financial Officer
M.Sc., MBA
Has more than 25 years of combined experience from biotech and financing.

Kaare G. Rasmussen
Head of Chemical Development
M.Sc. PhD
Has more than 20 years of CMC experience with a focus on drug manufacturing and project management

René Egebro
Head of Pharmaceutical Development
M.Sc.
Has more than 20 years of CMC experience with a focus on drug product- and analytical development

Mette Høy Jensen
Director Scientific Affairs
M.Sc., Ph.D.
Has more than seven years of Biotech experience running preclinical and clinical studies

News

Antag Therapeutics Announces FDA Clearance of Investigational New
Drug (IND) Application for Lead Molecule, AT-7687

OCTOBER 9, 2024

“We are thrilled to receive the FDA’s acceptance of our IND application for AT-7687,” said Alexander Sparre-Ulrich, CEO of Antag Therapeutics. “This marks a major step forward in advancing our clinical development program and brings us closer to providing a potential new treatment for patients with obesity and cardiometabolic diseases. We are excited to begin our Phase I study and further demonstrate the therapeutic potential of AT-7687 and GIPR antagonism.”

Read more

Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors

JULY 15, 2021

Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors.

Read more

Novo Seeds invests millions in diabetes venture with huge potential

JUNE 26, 2017

Denmark’s largest business newspaper (Børsen) covers Antag Therapeutic’s launch in this article

Read more

Novo Seeds invests millions in new venture

JUNE 26, 2017

MedWatch.dk covers the launch of Antag Therapeutics in the following article in Danish.

Read more